Steris Plc STE

Revenue Intelligence Report • 24 quarters of SEC filing data • Updated 2026-03-06

Steris Plc demonstrates strong revenue growth driven primarily by its investments in research and development, which yield a 2.34% increase in revenue for every 1% increase in R&D spending, alongside a 0.55% revenue increase from SG&A investments. With a model accuracy of 1.7% MAPE, the company has shown resilience, although a recent holdout test revealed a 7.5% prediction error. The fiscal year forecast projects a revenue of $6 billion, reflecting a solid 6.6% year-over-year growth. This outlook suggests a favorable return on investment for stakeholders, supported by strategic spending in key operational areas.

Next FY Revenue

$6.10B

+6.6% YoY

R&D Elasticity

2.34x

SG&A Elasticity

0.55x

Model Accuracy

1.7% MAPE

Holdout validation: The model predicted $1B vs the actual $1B — an error of 7.5%.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$1B	$1B	$1B – $1B	+4.2%	✗ Outside range
Q2 2026	$2B		$1B – $2B	+14.3%
Q3 2026	$1B		$1B – $2B	+1.7%
Q4 2026	$2B		$1B – $2B	+8.8%
Q1 2027	$2B		$1B – $2B	+2.1%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch